---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-029869"
form_type: "8-K/A"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:18:46.414544+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# AVROBIO amends 8-K: no material charges from cystinosis gene therapy asset sale

## Summary
- Amendment to prior 8-K (May 22, 2023) regarding sale of cystinosis gene therapy program.
- Company had previously been unable to estimate related charges; now determines no material charges expected.
- Asset sale includes all assets specifically related to the cystinosis gene therapy program.
- No change to other disclosures in the original Form 8-K.

## SEC filing metadata
- accession: 0001140361-23-029869
- form_type: 8-K/A
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000114036123029869/0001140361-23-029869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000114036123029869/brhc20054447_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-029869
- JSON: https://secwatch.observer/filing/0001140361-23-029869.json
- Plain text: https://secwatch.observer/filing/0001140361-23-029869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.